Eli Lilly and Co (LLY)
745.62
-4.30
(-0.57%)
USD |
NYSE |
Nov 22, 14:29
Eli Lilly Revenue (Annual): 34.12B for Dec. 31, 2023
Revenue (Annual) Chart
Historical Revenue (Annual) Data
Date | Value |
---|---|
December 31, 2023 | 34.12B |
December 31, 2022 | 28.54B |
December 31, 2021 | 28.32B |
December 31, 2020 | 24.54B |
December 31, 2019 | 22.32B |
December 31, 2018 | 21.49B |
December 31, 2017 | 19.97B |
December 31, 2016 | 21.22B |
December 31, 2015 | 19.96B |
December 31, 2014 | 19.62B |
December 31, 2013 | 23.11B |
December 31, 2012 | 22.60B |
December 31, 2011 | 24.29B |
December 31, 2010 | 23.08B |
December 31, 2009 | 21.84B |
December 31, 2008 | 20.37B |
December 31, 2007 | 18.63B |
December 31, 2006 | 15.69B |
December 31, 2005 | 14.65B |
December 31, 2004 | 13.86B |
Date | Value |
---|---|
December 31, 2003 | 12.58B |
December 31, 2002 | 11.08B |
December 31, 2001 | 11.54B |
December 31, 2000 | 10.86B |
December 31, 1999 | 10.00B |
December 31, 1998 | 9.237B |
December 31, 1997 | 7.988B |
December 31, 1996 | 6.998B |
December 31, 1995 | 6.764B |
December 31, 1994 | 5.712B |
December 31, 1993 | 6.452B |
December 31, 1992 | 6.167B |
December 31, 1991 | 5.726B |
December 31, 1990 | 5.192B |
December 31, 1989 | 4.176B |
December 31, 1988 | 4.070B |
December 31, 1987 | 3.644B |
December 31, 1986 | 3.720B |
December 31, 1985 | 3.271B |
December 31, 1984 | 3.109B |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Annual) Range, Past 5 Years
22.32B
Minimum
2019
34.12B
Maximum
2023
27.57B
Average
28.32B
Median
2021
Revenue (Annual) Benchmarks
Amgen Inc | 28.19B |
Biogen Inc | 9.836B |
Johnson & Johnson | 85.16B |
Viking Therapeutics Inc | -- |
Moderna Inc | 6.754B |